The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways

Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir induced lytic reactivation of Kapos...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jungang, Dai, Lu, Kendrick, Samantha, Post, Steven R., Qin, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923226/
https://www.ncbi.nlm.nih.gov/pubmed/35041508
http://dx.doi.org/10.1128/aac.02395-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923226/
https://www.ncbi.nlm.nih.gov/pubmed/35041508
http://dx.doi.org/10.1128/aac.02395-21

Ejemplares similares